Free Trial

Alumis (NASDAQ:ALMS) Stock Price Down 4.5% - Time to Sell?

Alumis logo with Medical background

Alumis Inc. (NASDAQ:ALMS - Get Free Report)'s stock price traded down 4.5% during trading on Wednesday . The stock traded as low as $12.39 and last traded at $12.39. 12,155 shares changed hands during mid-day trading, a decline of 93% from the average session volume of 166,725 shares. The stock had previously closed at $12.98.

Analyst Ratings Changes

ALMS has been the subject of a number of research reports. Leerink Partnrs upgraded shares of Alumis to a "strong-buy" rating in a research note on Tuesday, July 23rd. Morgan Stanley assumed coverage on Alumis in a research report on Tuesday, July 23rd. They issued an "overweight" rating and a $36.00 target price on the stock. Cantor Fitzgerald reissued an "overweight" rating on shares of Alumis in a report on Monday, August 19th. HC Wainwright began coverage on Alumis in a report on Thursday, October 17th. They issued a "buy" rating and a $30.00 price objective on the stock. Finally, Guggenheim assumed coverage on Alumis in a report on Tuesday, July 23rd. They set a "buy" rating and a $32.00 target price for the company. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $28.00.

View Our Latest Analysis on Alumis

Alumis Price Performance

The business has a 50-day moving average of $11.65.

Alumis (NASDAQ:ALMS - Get Free Report) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($23.10) EPS for the quarter, missing analysts' consensus estimates of ($1.57) by ($21.53). Equities research analysts anticipate that Alumis Inc. will post -6.86 earnings per share for the current fiscal year.

Institutional Trading of Alumis

Institutional investors and hedge funds have recently made changes to their positions in the company. Maven Securities LTD acquired a new position in Alumis during the second quarter valued at approximately $332,000. Millennium Management LLC acquired a new position in shares of Alumis during the 2nd quarter worth $3,376,000. Towerview LLC bought a new stake in shares of Alumis during the 2nd quarter worth $4,123,000. Ally Bridge Group NY LLC acquired a new stake in Alumis in the second quarter valued at about $8,229,000. Finally, Yu Fan bought a new position in Alumis in the second quarter valued at about $10,502,000.

Alumis Company Profile

(Get Free Report)

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.

Featured Articles

→ Algo Trading Is Here 🔥 (From Timothy Sykes) (Ad)

Should you invest $1,000 in Alumis right now?

Before you consider Alumis, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alumis wasn't on the list.

While Alumis currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Post-Election Chaos or Opportunity? Prepare Your Investments
Strong Markets Meet Rising Volatility—Are Your Investments Safe?
Analysts Bullish on AI-Powered Healthcare: Intuitive Surgical’s 30% Upside

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines